Education
About Us
Working with TipRanks
Follow Us
Rachel King Insider Profile
11 Followers
Rachel King, Director at Crescent Biopharma, holds 25.19K shares in Novavax (Ticker: NVAX), holds 659.10K shares in Crescent Biopharma (Ticker: CBIO), holds ― shares in Fulcrum Therapeutics (Ticker: FULC).
Profitable Transactions
2 out of 5 Profitable Transactions
Average Return
-15.30%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Rachel King holds in companies
Most Profitable Insider Trade
The most profitable trade made by Rachel King
Rachel King's Trading History
Crescent Biopharma
Apr 02, 2024
Director
Uninformative Buy
10.00K
$9.39M
Novavax
Jun 13, 2025
Director
Uninformative Buy
74.50K
$190.94K
Fulcrum Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Rachel King's performance on stock
You May Also Like
Rachel King insider profile FAQ
What is the percentage of profitable transactions made by Rachel King?
The percentage of profitable transactions made by Rachel King is 40%.
What is the average return per transaction made by Rachel King?
The average return per transaction made by Rachel King is -15.30%.
What stocks does Rachel King hold?
Rachel King holds: CBIO, NVAX, FULC stocks.
What was Rachel King’s latest transaction?
Rachel King latest transaction was an Uninformative Buy of $74.50K.
What was Rachel King's most profitable transaction?
Rachel King’s most profitable transaction was an Informative Buy of NVAX stock on March 28, 2019. The return on the trade was 20.80%.
What is Rachel King's role in Crescent Biopharma?
Rachel King's role in Crescent Biopharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.